Latest Threads on News from companies

Globalpharma, a subsidiary of Dubai Investments, has signed seven strategic Memorandums of Understanding (MoUs) with various partners to enhance its research and development, manufacturing, and sustainability efforts. These partnerships are organized into three strategic areas: innovation and product development, manufacturing efficiency and sustainability, and market access, financing, and expansion. Key partners include ZIM Laboratories and Molkem Chemicals for innovation, Masibus, Rockwell Automation, and 386 Sky Solar for manufacturing and sustainability, and Emirates Development Bank, Mubadala Bio’s Al Ittihad Drug Store, and Emirates Drug Establishment for market access and financing. The agreements aim to boost local capabilities, enable technology transfer, and support the UAE's pharmaceutical sector's growth and resilience. Globalpharma's CEO highlighted the focus on translating partnerships into operational outcomes, such as enhancing R&D capabilities, improving manufacturing efficiency through automation, and integrating sustainability measures. The collaboration with Emirates Drug Establishment also emphasizes pharmaceutical localization and regulatory alignment to strengthen local manufacturing and supply resilience.